FDA Commissioner Makary defends agency's decision on Replimune's drug
05/05/2026 15:56
May 5 (Reuters) - U.S. Food and Drug Administration Commissioner Dr. Marty Makary on Tuesday defended the agency's decision to not approve Replimune's REPL.O drug for advanced skin cancer.
"If you read our what we call our complete response letter, you will see the details of the FDA logic," Makary said in an interview on CNBC.
Replimune shares were down 5% in morning trading.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly